Precision medicine in thyroid nodules: current strategies, challenges, and future directions

Thyroid nodules represent a common clinical challenge, with ultrasound studies detecting them in 20–76% of adults. Although the majority are benign, malignancy occurs in approximately 5–15% of cases. Current diagnostic strategies integrate high-resolution ultrasound (e.g., TI-RADS), fine-needle aspiration cytology (Bethesda system), and molecular testing. For indeterminate nodules (Bethesda III/IV), classifiers such as Afirma® GSC and ThyroSeq® v3 show a 90–95% negative predictive value, which could reduce unnecessary surgeries by 30–33%. However, challenges remain, including limited accessibility, variable cost-effectiveness (USD 4,234–14,277 per avoided surgery), and difficulties in interpreting variants of uncertain significance. Emerging technologies show particular promise, including artificial intelligence (AI) applications in ultrasound interpretation (achieving 68–82% sensitivity, although performance decreases in external validation cohorts) and novel biomarkers like circulating tumor DNA and microRNA (miRNA) profiles. Precision medicine approaches now enable more tailored management, with active surveillance recommended for low-risk nodules and molecular profiling guiding surgical decision-making. Future directions include liquid biopsy techniques, improved dynamic risk stratification models, and enhanced integration of multiomics data. These advances aim to maintain excellent oncologic outcomes while minimizing overtreatment of indolent lesions. The field continues to evolve toward increasingly personalized care paradigms that balance diagnostic accuracy with quality-of-life considerations.